Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof inventions

20090275728 - Compound having histone deacetylase-inhibiting activity, and pharmaceutical composition comprising the compound as an active ingredient: A novel compound having histone deacetylase-inhibiting activity which is a cyclic tetrapeptide derivative represented by the general formula (1) given below and a pharmaceutical composition comprising such compound as an active ingredient. (In the formula, the cyclic tetrapeptide moiety has a known structure; R1 and R2 each independently represents an... Agent: Sughrue Mion, PLLC

20090275727 - Peptide turn mimetics: This invention provides novel compounds useful for the synthesis of peptide mimetics, and describes the use of these compounds for the synthesis of novel reverse turn mimetics. The reverse turn mimetics of the invention have the general structure X wherein the variables are as defined herein.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090275729 - Microrna and methods for inhibiting same: The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.... Agent: Hoffmann & Baron, LLP

20090275730 - Temperature responsive depsipeptide polymer: e

20090275731 - Method for producing protein: It has been required to refold an inactive protein into an active protein with high efficacy. This problem can be solved by the method for producing a protein including a step of providing a porous body supporting an inactive protein in its mesopores, a step of applying a denaturant to... Agent: Fitzpatrick Cella Harper & Scinto

20090275732 - Agent for improving circulatory disorder: Provided is a pharmaceutical agent capable of efficiently improving blood circulation in a region where a circulatory disorder occurs and fully preventing or improving tissue damage as a preventive or therapeutic agent for circulatory disorders in general. As a result of the study of pharmacological effects of a compound in... Agent: Kubovcik & Kubovcik

20090275733 - Production of mustard seed protein isolate: Mustard seed protein isolates are produced at a high purity level of at least about 100 wt % (N×6.25) by a process wherein mustard seed protein is extracted from mustard seed meal, the resulting aqueous mustard seed protein solution is concentrated to a mustard seed protein content of at least... Agent: Sim & Mcburney

20090275735 - Monoclonal antibodies to human ctla-8 (il-17a): Human CTLA-8 protein, antibodies that specifically bind to human CTLA-8, and nucleic acids encoding human CTLA-8. Methods of using these molecules and diagnostic kits are also provided.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090275734 - Pancreatic cancer genes: The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality... Agent: Novartis Vaccines And Diagnostics, Inc. Corporate Intellectual Property-r338

20090275736 - Nmdar biomarkers for diagnosis and treatment of traumatic brain injury and other disorders: Provided are methods for detecting various subunits and isoforms of NMDA receptors to help diagnose and differentiate (1) the anatomical location of NMDA receptor over-expression, (2) ischemic conditions in the central and peripheral nervous systems, and (3) the type and cause of chronic pain.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20090275737 - Immunogenic compositions and uses thereof: The present invention relates generally to a method of eliciting or otherwise inducing an effective immune response to a micro-organism and compositions for use therein. More particularly, the present invention relates to a method of inducing an immune response to a parasite utilising an immunogenic composition comprising a glycosylphosphatidylinositol (referred... Agent: Scully Scott Murphy & Presser, PC

20090275738 - Use of a33 antigens and jam-it: The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer.... Agent: Goodwin Procter LLP

20090275739 - Purification of glycopeptides: A novel and improved method for purification of glycopeptides, especially glycopeptide antibiotics. The method comprises contacting a solution of the glycopeptide to an ion exchange chromatography material. The product of this method has a surprisingly high purity.... Agent: Cantor Colburn, LLP

20090275740 - Novel collectin: Provided are isolated collectin (CL-L2s) genes including a base sequence set out in SEQ ID NO: 1, 3, 5, 7, 9, 12, 36, 38 or 40 relating to a novel collectin which are expected to exhibit an antibacterial activity, an antiviral activity and the like particularly in a human body;... Agent: Marshall, Gerstein & Borun LLP

20090275741 - Plants and seeds of corn variety cv678981: According to the invention, there is provided seed and plants of the corn variety designated CV678981. The invention thus relates to the plants, seeds and tissue cultures of the variety CV678981, and to methods for producing a corn plant produced by crossing a corn plant of variety CV678981 with itself... Agent: Sonnenschein Nath & Rosenthal LLP

20090270590 - Surface modified inorganic material and producing method thereof: A surface-modified inorganic material and a preparation method thereof. A surface-modified inorganic material is provided which is obtained by allowing an organosilane compound having allyl or an allyl derivative to react with an inorganic material, particularly solid silica or ITO glass, in the presence of an acid and an organic... Agent: D. Peter Hochberg Co. L.p.a.

20090270591 - Novel surface antigen: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N.... Agent: Proskauer Rose LLP

20090270593 - Nucleic acid binding substance containing catalytic nucleation nanoparticles: A nucleic acid binding substance having an affinity for nucleic acid polymers. The nucleic acid binding substance is comprised of a nucleic acid binding element capable of specific binding to nucleic acid molecules and connected to a catalytic nucleation particle... Agent: Hiscock & Barclay, LLP

20090270592 - Purified tnfr preparations: Purified protein preparations comprising tumor necrosis factor are disclosed.... Agent: Legal Affairs Department Immunex Corporation

20090270594 - Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies: The invention concerns the use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies... Agent: Arent Fox LLP

20090270595 - Il-1 related polypeptides: The present invention is directed to novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous... Agent: Genentech, Inc.

20090270596 - Chromatography purification of antibodies: Methods, kits and apparatuses for chromatography purification of antibodies are provided. In some embodiments, antibodies are purified by mixed mode chromatography that does not comprise hydroxyapatite (HT) or fluorapatite (FT). The mixed mode chromatography step is then followed by a HT/FT chromatography step.... Agent: Townsend And Townsend And Crew, LLP

20090270597 - Artificial antibody polypeptides: A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding said monobody, and a variegated nucleic acid library encoding said monobody, are provided by the invention. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform said methods. Further provided is a method of... Agent: Viksnins Harris & Padys Pllp

20090270598 - Amphiphiles for protein solubilization and stabilization: The invention provides amphiphiles for manipulating membrane proteins. The amphiphiles can feature carbohydrate-derived hydrophilic groups and branchpoints in the hydrophilic moiety and/or in a lipophilic moiety. Such amphiphiles are useful as detergents for solubilization and stabilization of membrane proteins, including photosynthetic protein superassemblies obtained from bacterial membranes.... Agent: Schwegman Lundberg & Woessner/warf

20090270599 - In situ heat induced antigen recovery and staining method: An automated in situ heat induced antigen recovery and staining method and apparatus for treating a plurality of microscope slides. The process of heat induced antigen recovery and the process of staining the biological sample on the microscope slide are conducted in the same apparatus, wherein the microscope slides do... Agent: Dunlap Codding, P.C.

20090264616 - Cyclodipeptide synthetases and their use for synthesis of cyclo(leu-leu) cyclodipeptide: Isolated, natural or synthetic polynucleotides and the polypeptides encoded by said polynucleotides, that are involved in the synthesis of cyclodipeptides, the recombinant vectors comprising said polynucleotides or any substantially homologous polynucleotides, the host cell modified with said polynucleotides or said recombinant vectors and also methods for in vitro and in... Agent: The Nath Law Group

20090264617 - Method of producing fr901228: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090264618 - Compounds with a branched linker: p

20090264619 - Metal-catalyzed copolymerization of imines and carbon monoxide as a route to synthesize polypeptides:

20090264620 - N-methylation of amino acids:

20090264621 - Lipid-assisted synthesis of polymer compounds and methods for their use: The invention herein disclosed provides for methods for the synthesis of polymers from monomers. In particular the method provides for the synthesis of polynucleotides from mononucleotides in the absence of catalytic enzymes. The invention is of particular use in the fields of molecular biology, structural biology, cell biology, molecular switches,... Agent: Bell & Associates

20090264624 - Human cytokine receptor: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.”... Agent: Darby/zymogenetics, Inc.

20090264622 - Rhesus monkey nur77: The Macaca mulatta (rhesus monkey) Nur77 (rhNur77) nuclear receptor and the nucleic acid encoding the rhNur77 nuclear receptor are described. Further described are methods for identifying analytes that modulate expression or activity of the rhNur77 nuclear receptor. Analytes that affect Nur77 expression or activity may be used to treat or... Agent: Merck And Co., Inc

20090264623 - Sodium channel protein type iii alpha-subunit splice variant: The present invention is directed to a splice variant of a human sodium channel alpha subunit and methods and compositions for making and using the same.... Agent: Marshall, Gerstein & Borun LLP

20090264625 - Method for recombinant microorganism expression and isolation of collagen-like polypeptides: A composition comprising a purified collagen-like polypeptide suitable as a peptizer, said polypeptide comprising [Gly-X-Y]n repeats, wherein Gly stands for glycine, X and Y represent any amino acid and n is an integer and selected such that the length of the [Gly-X-Y]n repeat is at least 2.5 kDa and wherein... Agent: Nixon & Vanderhye, PC

20090264626 - Stabilization of the collagen triple helix by o-methylation of hydroxyproline residues: This invention relates to a collagen polypeptide comprising a tripeptide motif having the formula (ProYaaGly)n, where Yaa is an O-methylated amino acid residue and “n” is the number of motif repeats. Preferred O-methylated amino acid residues at the Yaa position include (2S,4R)-4-methoxyproline. Other suitable amino acid residues at that position... Agent: Quarles & Brady LLP

20090264627 - Enhancing the circulating half-life of antibody-based fusion proteins: Disclosed are compositions and methods for enhancing the circulating half-life of antibody-based fusion proteins. Disclosed methods and compositions rely on altering the amino acid sequence of the junction region between the antibody moiety and the fused protein moiety in an antibody-based fusion protein. An antibody-based fusion protein with an altered... Agent: K&l Gates LLP

20090264628 - Crystal structure of human urokinase plasminogen activator amino teminal fragment bound to its receptor: Urokinase-type plasminogen activator (uPA) binds its cellular receptor (uPAR) with high affinity, thus localizing the generation of plasmin from plasminogen on the surface of a variety of cells. Disclosed herein is the structure of suPAR (uPAR1-277) complexed with the amino terminal fragment (ATF) of uPA (uPA1-143) at a resolution of... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090264629 - Stabilized protein-containing formulations: Protein formulations containing a poloxamer as a surfactant, and methods for maintaining the biological activity in protein formulations without adding an antioxidant and for inhibiting the formation of foreign insoluble matters by adding a poloxamer as a surfactant.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090264631 - Immunoadsorption of anti-von willebrand factor cleaving protease antibodies: This invention relates to adsorbents and methods for highly selective removal of anti-von Willebrand Factor-cleaving protease antibodies (“anti-vWF-cp-abs”) from human plasma using human von Willebrand Factor-cleaving protease (“hvWF-cp”) or fragments thereof as affinity ligands. The adsorbents can be used for treating disorders associated with the occurrence of anti-vWF-cp-abs in patients,... Agent: Baxter Healthcare Corporation

20090264630 - Method of separating monomeric protein(s): The present invention relates to a method of separating one or more monomeric proteins, such as monomeric antibodies, from a liquid. The method comprises providing a thiophilic aromatic chromatography matrix; contacting the liquid that comprises proteins with the matrix; and recovering at least one monomeric protein, such as a monomeric... Agent: Ge Healthcare Bio-sciences Corp. Patent Department

20090264632 - Device and a method for promoting crystallisation: The invention relates to a microfluidic device for promoting crystallisation of target molecules, such as proteins. The device comprises a solid structure with a top face and an opposite bottom face and with a least one liquid channel. The liquid channel comprises a target molecule solution inlet and at least... Agent: Buchanan, Ingersoll & Rooney PC